
Similar Outcomes and Prognosis between Osteoblastic Cell vs Standard Therapy in Patients with ONFH

Similar Outcomes and Prognosis between Osteoblastic Cell vs Standard Therapy in Patients with ONFH
Did Osteoblastic Cell Therapy Improve the Prognosis of Pre-fracture Osteonecrosis of the Femoral Head? A Randomized, Controlled Trial
Clin Orthop Relat Res. 2020 Jun;478(6):1307-1315.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
Fifty-nine patients were randomized into receiving bone marrow aspirate concentrate (BMAC) or osteoblastic cell therapy for the treatment of nontraumatic osteonecrosis of the femoral head (ONFH). The primary outcomes included fracture progression as well as improvement in pain and functionality, which were all measured at 36 months. The secondary outcomes consisted of the proportion of hips conver...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!

Learn about our AI Driven
High Impact Search Feature

The OE High Impact metric uses AI to determine the impact a study will have by considering the content of the article itself. Built using the latest advances of natural language processing techniques. OE High Impact predicts an article’s future number of citations than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.